Literature DB >> 11774237

Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.

Lars Damstrup1, Mikkel Wandahl Pedersen, Lone Bastholm, Folmer Elling, Hans Skovgaard Poulsen.   

Abstract

In the present study we transfected the epidermal growth factor receptor (EGFR)-negative small cell lung cancer cell line, GLC3, with the type III EGFR mutation (EGFRvIII). The EGFRvIII protein could be detected by Western blot analysis as a 145-kDa protein, which by immunohistochemistry appeared to be localized at the cell surface. Ultrastructurally EGFRvIII was expressed mainly at the cell surface with clusters at cell-cell contacts. In the in vitro invasion assay, GLC3-EGFRvIII cells had a approximately 5-fold increased invasion compared with uninduced GLC3-EGFRvIII, GLC3-Tet-On and the parental cell line. GLC3-Tet-On appeared uniform in size with adherence junctions at cell-cell contacts. In uninduced GLC3-EGFRvIII cells adherence junctions were also present but less distinct. In doxycycline-pretreated GLC3-EGFRvIII cells, adherence junctions were absent. We conclude that the expression of EGFRvIII results in a more malignant phenotype. This effect appears to involve the disruption of adherence junctions. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774237     DOI: 10.1002/ijc.1572

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.

Authors:  Massod Rahimi; Kai-Ling Huang; Careen K Tang
Journal:  Cancer Lett       Date:  2010-03-17       Impact factor: 8.679

2.  EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.

Authors:  Massod Rahimi; Jessica George; Careen Tang
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

3.  Laminin alpha2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: a model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasis.

Authors:  Domenico Vitolo; Luciano Ciocci; Gloria Deriu; Silvia Spinelli; Stefania Cortese; Laura Masuelli; Stefania Morrone; Mary Jo Filice; Giorgio Furio Coloni; Pier Giorgio Natali; Carlo Davide Baroni
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

4.  E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells.

Authors:  Guido Lammering; Marc Vooijs; Jan Theys; Barry Jutten; Roger Habets; Kim Paesmans; Arjan J Groot; Philippe Lambin; Brad G Wouters
Journal:  Radiother Oncol       Date:  2011-06-15       Impact factor: 6.280

5.  EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.

Authors:  G C Davies; P E Ryan; L Rahman; M Zajac-Kaye; S Lipkowitz
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

6.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

Review 7.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

9.  Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses.

Authors:  Mm Ivanova; Sm Abner; Wm Pierce; Cm Klinge
Journal:  Proteome Sci       Date:  2011-09-27       Impact factor: 2.480

10.  Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

Authors:  M W Pedersen; N Pedersen; L H Ottesen; H S Poulsen
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.